Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean M Connors

Showing results (31-40 of 277) with videos related to

Pageof 28
Sort By:
Blood|April 28, 2020
COVID-19 and its implications for thrombosis and anticoagulationJean M Connors, Jerrold H Levy
The New England Journal of Medicine|August 26, 2021
Heparin Resistance - Clinical Perspectives and Management StrategiesJerrold H Levy, Jean M Connors
Journal of Cardiothoracic and Vascular Anesthesia|October 17, 2020
Andexanet Alfa Use in Cardiac Surgical Patients: A Xa Inhibitor and Heparin Reversal AgentJerrold H Levy, Jean M Connors
Current Opinion in Endocrinology, Diabetes, and Obesity|October 10, 2009
Management of inherited thrombophilia in pregnancyAnnemarie E Fogerty, Jean M Connors
JACC. Cardiooncology|March 21, 2024
The Pursuit of "Best" Anticoagulant for Cancer-Associated Thrombosis: Are We There Yet?Tzu-Fei Wang, Jean M Connors
Journal of Thrombosis and Haemostasis : JTH|April 18, 2020
Thromboinflammation and the hypercoagulability of COVID-19Jean M Connors, Jerrold H Levy
Journal of Thrombosis and Haemostasis : JTH|March 1, 2023
Evaluation and management of oral anticoagulant bleeding: quid didicimus? (what have we learned?)Jerrold H Levy, Jean M Connors
Hematology/Oncology Clinics of North America|March 30, 2011
Treating venous thromboembolism in pregnancyAnnemarie E Fogerty, Jean M Connors
JAMA|March 22, 2022
Thromboinflammation and Antithrombotics in COVID-19: Accumulating Evidence and Current StatusJean M Connors, Paul M Ridker
Journal of Thrombosis and Thrombolysis|June 23, 2019
Cost-effectiveness of edoxaban versus dalteparin for the treatment of cancer-associated thrombosisNathan T Connell, Jean M Connors
Pageof 28

Showing results (31-40 of 277) with videos related to

Sort By:
Pageof 28
Blood|April 28, 2020
COVID-19 and its implications for thrombosis and anticoagulationJean M Connors, Jerrold H Levy
The New England Journal of Medicine|August 26, 2021
Heparin Resistance - Clinical Perspectives and Management StrategiesJerrold H Levy, Jean M Connors
Journal of Cardiothoracic and Vascular Anesthesia|October 17, 2020
Andexanet Alfa Use in Cardiac Surgical Patients: A Xa Inhibitor and Heparin Reversal AgentJerrold H Levy, Jean M Connors
Current Opinion in Endocrinology, Diabetes, and Obesity|October 10, 2009
Management of inherited thrombophilia in pregnancyAnnemarie E Fogerty, Jean M Connors
JACC. Cardiooncology|March 21, 2024
The Pursuit of "Best" Anticoagulant for Cancer-Associated Thrombosis: Are We There Yet?Tzu-Fei Wang, Jean M Connors
Journal of Thrombosis and Haemostasis : JTH|April 18, 2020
Thromboinflammation and the hypercoagulability of COVID-19Jean M Connors, Jerrold H Levy
Journal of Thrombosis and Haemostasis : JTH|March 1, 2023
Evaluation and management of oral anticoagulant bleeding: quid didicimus? (what have we learned?)Jerrold H Levy, Jean M Connors
Hematology/Oncology Clinics of North America|March 30, 2011
Treating venous thromboembolism in pregnancyAnnemarie E Fogerty, Jean M Connors
JAMA|March 22, 2022
Thromboinflammation and Antithrombotics in COVID-19: Accumulating Evidence and Current StatusJean M Connors, Paul M Ridker
Journal of Thrombosis and Thrombolysis|June 23, 2019
Cost-effectiveness of edoxaban versus dalteparin for the treatment of cancer-associated thrombosisNathan T Connell, Jean M Connors
Pageof 28